Therapeutic advances in multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …
causes significant disability and healthcare burden. The treatment of MS has evolved over …
Neuroimmune disorders in COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the aetiologic agent of the
coronavirus disease 2019 (COVID-19), is now rapidly disseminating throughout the world …
coronavirus disease 2019 (COVID-19), is now rapidly disseminating throughout the world …
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis
A Salter, RJ Fox, SD Newsome, J Halper… - JAMA …, 2021 - jamanetwork.com
Importance Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather
information on clinical outcomes and risk factors associated with morbidity and mortality in …
information on clinical outcomes and risk factors associated with morbidity and mortality in …
[HTML][HTML] Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global …
Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …
Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis
Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for
severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive …
severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive …
Humoral-and T-cell–specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies
Background and Objectives To evaluate the immune-specific response after full severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination of patients with …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination of patients with …
[HTML][HTML] COVID-19 mRNA vaccination leading to CNS inflammation: a case series
The availability of vaccines against the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), provides hope towards mitigation of the coronavirus disease 2019 (COVID …
(SARS-CoV-2), provides hope towards mitigation of the coronavirus disease 2019 (COVID …
Robust T-cell responses in anti-CD20-treated patients following COVID-19 vaccination: a prospective cohort study
Background Patients treated with anti-CD20 therapy are particularly at risk of develo**
severe coronavirus disease 2019 (COVID-19); however, little is known regarding COVID-19 …
severe coronavirus disease 2019 (COVID-19); however, little is known regarding COVID-19 …
COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies
AT Reder, D Centonze, ML Naylor, A Nagpal… - CNS drugs, 2021 - Springer
Abstract Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target
immunity and have the potential to increase the risk of severe acute respiratory syndrome …
immunity and have the potential to increase the risk of severe acute respiratory syndrome …